Clinical Trial

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 5, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Ixazomib combined with low-dose lenalidomide(10mg) vs Ixazomib alone as maintenance regimen in patients with high-risk multiple myeloma after induction and consolidation of VRD-based regimen.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT05722405
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: Affiliated Hospital of Jiaxing University, Huzhou Central Hospital, Lishui Country People's Hospital, Dongyang People's Hospital, Shangyu People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital
Conditions Multiple Myeloma
Enrollment 100 participants
Start Date 2022-07-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-05